share_log
Moomoo 24/7 ·  Apr 15 17:16
SAB Biotherapeutics: on April 12, Completed Dosing of Cohort 3 for Phase One Trials of SAB-142, Has Not Observed Any Instances of Serum Sicknesses
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment